A CHOP-21 course efficacy in therapy of diffuse large B-cell lymphosarcoma

A. U. Magomedova, S. K. Kravchenko, A. M. Kremenetskaya, E. E. Zvonkov, T. N. Moiseeva, E. E. Zybunova, I. B. Kaplanskaya, R. S. Samoilova, I. A. Vorobyev, Yu Yu Lorie, O. V. Margolin, E. A. Gilyazitdinova, A. V. Gubkin, N. G. Chernova, V. V. Ryzhko, E. G. Gemdzhan

Research output: Contribution to journalArticlepeer-review

1 Citation (Scopus)

Abstract

Aim. To examine efficacy of polychemotherapy (PCT) CHOP-21 in patients with diffuse large B-cell lymphosarcoma (DLBCL). Material and methods. Fifty-five DLBCL patients received first-line therapy according to CHOP-21 program in 1996-2004. The diagnosis was made by WHO criteria. Results. Initially, 37 patients had lymph node lesions, 18 - nonlymphatic lesions. Complete remissions were achieved in 49% (56.7% in nodal lesions, 33.3% in extranodal ones). Overall 5-year survival was 35%, event-free - 25%, for patients with nodal lesions - 36 and 32%, respectively, extranodal lesions - 35 and 22%, respectively. Overall 5-year and event-free survival in patients with local lesions was 85 and 75%, generalized - 25 and 20%, respectively. In patients with involvement of the gastrointestinal tract 3-year overall and event-free survival reached 50 and 45%. Event-free survival was not seen in patients with extranodal lesions of other locations in overall 3-year survival 45%. Conclusion. PCT program CHOP-21 was effective in DLBCL patients with local nodular lesions except cases with large-size tumors, invasion in the adjacent organs and tissues and isolated gastric lesion.

Original languageEnglish
Pages (from-to)58-61
Number of pages4
JournalTerapevticheskii Arkhiv
Volume77
Issue number7
Publication statusPublished - Aug 22 2005

Keywords

  • CHOP-21
  • Diffuse large B-cell lymphosarcoma
  • Extranodal
  • Generalized lesion
  • Local
  • Nodal
  • Survival

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism

Fingerprint Dive into the research topics of 'A CHOP-21 course efficacy in therapy of diffuse large B-cell lymphosarcoma'. Together they form a unique fingerprint.

Cite this